In a landmark move, the Supreme Court of India refused to block Natco Pharma from producing a low-cost version of Roche’s SMA drug, Evrysdi, marking a powerful stand for affordable healthcare. The Roche-Natco SMA drug patent dispute underscores India’s constitutional commitment to prioritize life over profit, reaffirming its legacy as the world’s pharmacy.